Supplementary Table 2 from Germline Mutations as Cancer Drug Targets

Supplementary Table 2 from Germline Mutations as Cancer Drug Targets

<p>Supplementary Table 2: Gene Content and Associated Phenotypes of Different Germline Panels in April 2024</p>

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Tin-Yun Tang (17535130) (author)
Այլ հեղինակներ:	Karen Colbert Maresso (16494623) (author), Joanne Ngeow (9563452) (author), Eduardo Vilar (14938758) (author), Timothy A. Yap (15028749) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Cancer Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Epidemiology Biomarkers Cancer risk biomarkers Dna Damage And Repair Drug Targets Genetics of Cancer Risk & Outcome Familial and hereditary cancers Oncogenes & Tumor Suppressors
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

Նմանատիպ նյութեր

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
‌: Lenka Stolarova (16547259)
Հրապարակվել է: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
‌: Lenka Stolarova (16547259)
Հրապարակվել է: (2025)

Table S3 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
‌: Lenka Stolarova (16547259)
Հրապարակվել է: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
‌: Sami Belhadj (15052341)
Հրապարակվել է: (2025)

Supplementary Tables 1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
‌: Prashant Chittiboina (15367044)
Հրապարակվել է: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
‌: Min Wei (16918572)
Հրապարակվել է: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
‌: Min Wei (16918572)
Հրապարակվել է: (2025)

Supplementary Data from Genome-Wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk
‌: Fan Wang (14963418)
Հրապարակվել է: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Table S1 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
‌: Xianbing Zhu (18366906)
Հրապարակվել է: (2025)

Table S2 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
‌: Xianbing Zhu (18366906)
Հրապարակվել է: (2025)

Table S3 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
‌: Xianbing Zhu (18366906)
Հրապարակվել է: (2025)

Table S4 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
‌: Xianbing Zhu (18366906)
Հրապարակվել է: (2025)

Table S5 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
‌: Xianbing Zhu (18366906)
Հրապարակվել է: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure 4 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
‌: Luiza Doro Pereira (20749876)
Հրապարակվել է: (2025)

Figure 2 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
‌: Luiza Doro Pereira (20749876)
Հրապարակվել է: (2025)